Filing Flows › Lyell Immunopharma (LYEL) › Q3 2025
Lyell Immunopharma (LYEL) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 12, 2025
Lyell Immunopharma (LYEL) reported revenue of $15K for the third quarter 2025 (Q3 2025), -56% from a year earlier and +88% from the quarter before.
Lyell Immunopharma, Q3 2025: revenue $15K (-56% year over year), net loss $38.8M, operating cash flow −$28.6M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $15K | +88% | -56% |
| Operating profit | −$37.3M | — | — |
| Net earnings | −$38.8M | — | — |
| Operating cash flow | −$28.6M | — | — |
What changed
Revenue was $15K in Q3 2025, down 56% year over year and up 88% from the previous quarter.
Operating costs exceeded revenue by $37.3M, an operating margin of -248353.3%. Total costs fell 26% while revenue fell 56%. The quarter ended with a net loss of $38.8M, narrower than the previous quarter's $42.7M loss.
Operating cash flow was −$28.6M. Non-cash charges added back $2.6M of depreciation and amortization and $5.2M of share-based compensation. Working capital and other items added $2.5M. Capital expenditures of $62K exceeded it, leaving free cash flow of −$28.6M.
Questions
What was Lyell Immunopharma's revenue in the third quarter 2025?
Lyell Immunopharma (LYEL) reported revenue of $15K for the third quarter 2025 (Q3 2025), -56% from a year earlier and +88% from the quarter before.
Source: Lyell Immunopharma 10-Q on SEC EDGAR.